Credit: mannKind. Furoscix ReadyFlow offers a rapid, outpatient alternative for acute fluid overload management in heart failure and chronic kidney disease. Furoscix ReadyFlow demonstrated a ...
Kalshi starts prediction market for clinical trials and FDA approvals; positive results shared for triple hormone receptor agonist therapy retatrutide; Jideytro gains approval in advanced or ...
These findings can guide development of AGS surveillance systems and help identify regions with increased risk. HealthDay News — The estimated seroprevalence of alpha-gal immunoglobulin E (IgE) ...
The oral RAS(ON) multi-selective inhibitor nearly doubled overall survival compared with investigator’s choice chemotherapy in the phase 3 RASolute 302 trial.
Retatrutide 12mg achieved up to 22.6% (55.8 lbs) mean weight loss at week 80, alongside marked improvements in ...
Lu AH69593 is currently being evaluated in a phase 1b clinical trial in healthy adults and patients with narcolepsy type 1. The Food and Drug Administration (FDA) has granted Fast Track designation to ...
The analysis included 75 brick-and-mortar weight-loss clinics and medical spas offering compounded GLP-1 RAs. HealthDay News — Despite the end of nationwide shortages of glucagon-like peptide-1 ...
One in about 7300 individuals in the general population have PMS, a rare genetic condition that causes medical, intellectual, and behavioral challenges.
In a scientific statement, the association states that consuming caffeinated coffee linked to reduced risks for type 2 diabetes, heart disease, stroke, heart failure.
For patients aged 4 to 66 years with acquired hypothalamic obesity, setmelanotide leads to significantly greater reductions ...
Jideytro is FDA-approved for adult patients with locally advanced or metastatic ROS1-positive NSCLC who received prior ROS1 TKI therapy.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results